HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autoantibodies to the atheroma component beta2-glycoprotein I and risk of symptomatic peripheral artery disease.

Abstract
Peripheral artery disease (PAD) is mostly related to atherosclerosis. Autoimmunity and, in particular, antibodies to cardiolipin (aCL) and phospholipid cofactors such as beta2-glycoprotein I (beta2-gpI) might influence the development of atheroma. Beta2-glycoprotein I (beta2-gpI) has been found in atheroma. It has previously been shown that immunoglobulin A (IgA) anti-beta2-gpI antibodies are associated with a risk of cerebral ischemia and myocardial infarction. This case control study aimed to determine whether elevated levels of aCL/anti-beta2-gpI antibodies are associated with a risk of symptomatic PAD (sPAD). Cases comprised a nonselected population of patients with sPAD (intermittent claudication or critical ischemia). Patient recruitment was based on arteriography changes. Controls were selected from patients admitted to orthopedic wards as a result of fractures or muscle-ligamentous disorders. Age, sex, race, hypertension, smoking, diabetes mellitus, and hypercholesterolemia were evaluated as risk factors in both groups. IgG/IgM/IgA aCL and anti-beta2-gpI were detected by enzyme-linked immunoabsorbant assays (ELISA). To estimate the grade of association of antibodies with sPAD, odds ratios (OR) were calculated. Logistic regression was utilized for adjustment of confounding factors. Seventy-seven cases and 93 controls were studied. The mean age was 61.5 years for cases and 47.5 years for controls (p <0.001). Among the risk factors evaluated, the presence of hypertension showed the strongest association with sPAD (OR 12.1; 95%CI 5.8-30). The presence of IgA anti-beta2-gpI was independently associated with sPAD (OR 5.4; 95%CI 1.8-15.8; p = 0.01). IgA aCL was strongly associated with the outcome (nonadjusted OR 11.5 after Agresti correction). IgA aCL and IgA anti-beta2-gpI antibodies were not associated with any known risk factors for sPAD or with arteriography changes. The occurrence of these autoantibodies might represent one of the links between autoimmunity and atherosclerosis in patients with sPAD.
AuthorsMarcus Franck, Henrique L Staub, João B Petracco, Gary L Norman, Andrew J Lassen, Nádia Schiavo, Rodrigo B K Borges, Carlos A von Mühlen
JournalAngiology (Angiology) 2007 Jun-Jul Vol. 58 Issue 3 Pg. 295-302 ISSN: 0003-3197 [Print] United States
PMID17626983 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Anticardiolipin
  • Autoantibodies
  • beta 2-Glycoprotein I
Topics
  • Adult
  • Aged
  • Antibodies, Anticardiolipin (blood)
  • Atherosclerosis (epidemiology, immunology)
  • Autoantibodies (blood)
  • Autoimmunity
  • Case-Control Studies
  • Diabetes Complications (immunology)
  • Female
  • Humans
  • Hypercholesterolemia (complications)
  • Hypertension (complications)
  • Incidence
  • Logistic Models
  • Male
  • Middle Aged
  • Odds Ratio
  • Peripheral Vascular Diseases (epidemiology, immunology)
  • Risk Assessment
  • Risk Factors
  • Smoking (adverse effects)
  • beta 2-Glycoprotein I (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: